tbuckley/cabot-search huggingface dataset:
642TiP Phase II CA184-585 (INSPIRE) trial of ipilimumab with nivolumab for molecular-selected patients with castration-resistant prostate cancer
Authors: N. Mehra, I. Kloots, P. Slootbeek, M. den Brok, G. Adema, L. Kerkmeijer, R.J. Smeenk, H. Westdorp, H. Bloemendal, J. Schalken, N.P. van Erp, M. Binder, J. De Vries, W. Gerritsen
Journal: Annals of Oncology (2021)
944P Adjuvant camrelizumab combined with apatinib treatment after resection of hepatocellular carcinoma in CNLC II and III stage: A single-center prospective phase II trial
Authors: X. Yang, H. Sun, B. Hu, S-Y. Wu, Y-H. Shi, X-Y. Wang, Q. Gao, C. Huang, Z. Wang, G-M. Shi, None Y-F. he, Z-B. Ding, Y-F. Peng, J. Sun, X-W. Huang, Q-H. Ye, S-J. Qiu, J. Zhou, J. Fan
Journal: Annals of Oncology (2021)
Abstract 10075: Residual Gensini Score is Associated With Long Term Cardiac Mortality in Patients With Ischemic Heart Failure
Authors: Tetsuro Yokokawa, Akiomi Yoshihisa, Takuya Ando, Takatoyo Kiko, Takeshi Shimizu, Takayoshi Yamaki, Hiroyuki Kunii, Kazuhiko Nakazato, Takafumi Ishida, Yasuchika Takeishi
Journal: Circulation (2019)

Background: Coronary revascularization is important for heart failure patients with ischemic etiology. However, long-term prognostic impact of residual stenosis after revascularization is still poo...
454P CCR5/CCL5 gene expression in colorectal cancer (CRC): Comprehensive profiling and clinical value
Authors: F. Battaglin, J. Baca, J. Xiu, A.F. Shields, R.M. Goldberg, H. Arai, J. Wang, P. Jayachandran, N. Kawanishi, A. Lenz, S. Soni, A. Seeber, J. Abraham, E. Lou, P.A. Philip, B.A. Weinberg, W. Zhang, J.L. Marshall, W.M. Korn, H-J. Lenz
Journal: Annals of Oncology (2021)
Sound sleep: Lullabies as a test case for the neurobiological effects of music
Authors: Miriam Akkermann, Ugur Can Akkaya, Cagatay Demirel, Dirk Pflüger, Martin Dresler
Journal: Behavioral and Brain Sciences (2021)

Abstract Music is part of the cultural practice and, at the same time, is interwoven with biology through its effects on the brain and its likely evolutionary origin. Studies on music, however, are traditionally based on the humanities and often carried out in a purely historical context, without much input from neuroscience and biology. Here, we argue that lullabies are a particularly suited test case to study the biological versus cultural aspects of music.
232P Longitudinal circulating tumor DNA (ctDNA) analysis in the phase 1b MONALEESASIA study of ribociclib (RIB) + endocrine therapy (ET) in Asian patients (pts) with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC)
Authors: Y.S. Yap, F. Su, M. Joshi, J. Chiu, N. Masuda, Y. Ito, T. Ishikawa, T. Aruga, S.J. Kim, U. Deore, N. Babbar, A. Balbin
Journal: Annals of Oncology (2021)
Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis
Authors: Baris Gencer, Luc Djousse, Omar T. Al-Ramady, Nancy R. Cook, JoAnn E. Manson, Christine M. Albert
Journal: Circulation (2021)

Some, but not all, large-scale randomized controlled trials (RCTs) investigating the effects of marine ɷ-3 fatty acids supplementation on cardiovascular outcomes have reported increased risks of atrial fibrillation (AF). The potential reasons for disparate findings may be dose-related.
COVID-19 and global equity for health: The good, the bad, and the wicked
Authors: Elvin H. Geng, Michael J. A. Reid, Eric Goosby, Quarraisha Abdool-Karim
Journal: PLoS Medicine (2021)

Many problems underscored by the Coronavirus Disease 2019 (COVID-19) pandemic, and highlighted in other papers in this collection [1], center on addressing the grossly unequal availability of vaccine around the world.The problem of equity in the public health response fits Rittel and Webber's conceptualization of "wicked problems" [2] that describe complex issues that defy conventional scientific analyses.Wicked problems have many characteristics, but three stand out when contemplating an equitable response to the COVID-19 pandemic.First, wicked problems have no definitive problem statement because understanding the problem is the crux of the problem itself.Is an equitable response to COVID-19 the problem, or is inequity in vaccines a symptom of larger inequity in health, economic, and societal systems?And is the problem equity in distribution, or is the root problem scarcity due to unfair trade arrangements?Second, in wicked problems, the elusive problem formulation precludes a shared understanding of success, or even progress, by stakeholders.What would constitute an acceptably equitable response?How would we measure progress without a unified direction?Third, in wicked problems, the absence of a shared agenda (and measures of progress) undermines aligned and effective action.Without true consensus that a fair allocation of vaccines across countries is based on population size instead of disease burden (as proposed by COVAX), targets based on progress toward such a distribution would lack real commitment from global stakeholders.The answers are as critical as they are elusive, not only for how the COVID-19 pandemic evolves, but also for whether we learn from it to better navigate future threats.COVID-19 is not the first wicked problem evident in global public health, however, and the recent past may offer some lessons.Three decades ago, HIV presented an urgent, complex, dynamic, and wicked threat to health around the world in which global inequities were stark and unacceptable.In 2004, 39 million people were living with HIV, 4.9 million new infections occurred, and 3.1 million died of HIV (comparable to the approximately 3.1 million COVID-19 deaths by April 16, 2021) in that year, the vast majority of new infections (>95%) and deaths (>95%) occurred in lower and middle-income countries.At the time, lifesaving antiretroviral therapy was available only in high-income countries, where it was expensive, delivered by highly trained specialists, and accompanied by sophisticated monitoring requirements (e.g., quantitative HIV plasma RNA levels and genotypical analysis).Naysayers warned that providing treatment throughout the world to close these major gaps would lead to "antiretroviral anarchy" and widespread drug resistance.To make progress against HIV, and increase equitability around the world, the world faced many of the same problems that we face today.Was
1399P Risk factors for body weight loss after gastrectomy for gastric cancer analysed from the JCOG1001 phase III trial
Authors: T. Yamada, Y. Kurokawa, J. Mizusawa, A. Takeno, J. Hihara, H. Imamura, A. Takagane, S. Nunobe, H. Fukuda, S. Takiguchi, Y. Doki, N. Boku, T. Yoshikawa, M. Terashima, T. Sano, M. Sasako
Journal: Annals of Oncology (2021)
Genomic sequencing and functional analyses identify MAP4K3/GLK germline and somatic variants associated with systemic lupus erythematosus
Authors: Huai-Chia Chuang, Wei-Ting Hung, Yi-Ming Chen, Pu-Ming Hsu, Jeng-Hsien Yen, Joung-Liang Lan, Tse-Hua Tan
Journal: Annals of the Rheumatic Diseases (2021)

Objectives MAP4K3 (GLK) overexpression in T cells induces interleukin (IL)-17A production and autoimmune responses. GLK overexpressing T-cell population is correlated with severity of human systemic lupus erythematosus (SLE); however, it is unclear how GLK is upregulated in patients with SLE. Methods We enrolled 181 patients with SLE and 250 individuals without SLE (93 healthy controls and 157 family members of patients with SLE) in two independent cohorts from different hospitals/cities. Genomic DNAs of peripheral blood mononuclear cells were subjected to next-generation sequencing to identify GLK gene variants. The functional consequences of the identified GLK germline or somatic variants were investigated using site-directed mutagenesis and cell transfection, followed by reporter assays, mass spectrometry, immunoblotting, coimmunoprecipitation, and in situ proximity ligation assays. Results We identified 58 patients with SLE from Cohort #1 and #2 with higher frequencies of a somatic variant (chr2:39 477 124 A&gt;G) in GLK 3′-untranslated region (UTR); these patients with SLE showed increased serum anti-double-stranded DNA levels and decreased serum C3/C4 levels. This somatic variant in 3′-UTR enhanced GLK mRNA levels in T cells. In addition, we identified five patients with SLE with GLK (A410T) germline variant in Cohort #1 and #2, as well as two other patients with SLE with GLK (K650R) germline variant in Cohort #1. Another GLK germline variant, A579T, was also detected in one patient with SLE from Cohort #2. Both GLK (A410T) and GLK (K650R) mutants inhibited GLK ubiquitination induced by the novel E3 ligase makorin ring-finger protein 4 (MKRN4), leading to GLK protein stabilisation. Conclusions Multiple GLK germline and somatic variants cause GLK induction by increasing mRNA or protein stability in patients with SLE.
CN8 The feasibility and utility of a mobile app in supporting Vietnamese children with cancer
Authors: N.H.C. Duc, N. Ha Xuan, H. Pham Nhu, T.N. Nguyen Thi, H.T. Nguyen Thi, T.T. Nguyen Thi, N. Hong Duyen, N. Khoi Quan, N.H. Minh Trang, T. Kiem Hao, C. Van Ha, N.T. Diem Chi, N. Thanh Xuan, N. Huu Son, Q. Pham Nguyen, T. Kondo, S. Matsumoto
Journal: Annals of Oncology (2021)
1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)
Authors: R-H. Xu, F. Wang, C. Cui, J. Yao, Y. Zhang, G. Wang, J. Feng, S. Yang, Y. Fan, J. Shi, X. Zhang, L. Shen, Y. Shu, C. Wang, T. Dai, T. Mao, L. Chen, Z. Guo, B. Liu, H. Pan
Journal: Annals of Oncology (2021)
Developing a Reflexive, Anticipatory, and Deliberative Approach to Unanticipated Discoveries: Ethical Lessons from iBlastoids
Authors: Rachel A. Ankeny, Megan J. Munsie, Joan Leach
Journal: The American Journal of Bioethics (2021)

In this paper, we explore the recent creation of "iBlastoids," which are 3-D structures that resemble early human embryos prior to implantation which formed via self-organization of reprogrammed adult skin cells. We explore some of the ethical, philosophical, social, and regulatory issues related to this research, with focus particularly on what it means to "anticipate" research outcomes when using novel methods or when serendipitous discoveries are made. We defend the need for reflexive, anticipatory, and deliberative ethical and conceptual work by researchers working in emerging and contentious research domains, in collaboration with interdisciplinary scholars, as well as regulators, funders, and publics.
662P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non–clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B
Authors: J-L. Lee, D.F. McDermott, M. Ziobro, C. Suarez, P. Langiewicz, V.B. Matveev, P. Wiechno, R. Gafanov, P. Tomczak, F. Pouliot, F. Donskov, B.Y. Alekseev, S.J. Shin, G.A. Bjarnason, D. Castellano, H. Liu, J. Burgents, K. Rodriguez-Lopez, M.B. Atkins
Journal: Annals of Oncology (2021)
Exposure to nanoplastics impairs collective contractility of neonatal cardiomyocytes under electrical synchronization
Authors: Amir Roshanzadeh, Nomin-Erdene Oyunbaatar, Sarina Ehteshamzadeh Ganjbakhsh, Sangwoo Park, Dong-Su Kim, Pooja P. Kanade, Seongsoo Lee, Dong-Weon Lee, Eung-Sam Kim
Journal: Biomaterials (2021)
457P Circulating tumor DNA (ctDNA) from patients (pts) with advanced colorectal cancer (CRC) is enriched for EGFR extracellular domain (ECD) mutations
Authors: S. Tejpar, H. Tukachinsky, L. Zhang, A.B. Schrock, B. Decker, D.C. Pavlick, J. Venstrom, H. Nimeiri, G. Oxnard
Journal: Annals of Oncology (2021)
Author Correction: Fatty acid synthesis is required for breast cancer brain metastasis
Authors: Gino B. Ferraro, Ahmed Ali, Alba Luengo, David P. Kodack, Amy Deik, Keene L. Abbott, Divya Bezwada, Landry Blanc, Brendan Prideaux, Xin Jin, Jessica M. Posada, Jiang Chen, Christopher R. Chin, Zohreh Amoozgar, Raphael Ferreira, Ivy X. Chen, Kamila Naxerova, Christopher Ng, Anna M. Westermark, Mark Duquette, Sylvie Roberge, Neal I. Lindeman, Costas A. Lyssiotis, Jens Nielsen, David E. Housman, Dan G. Duda, Elena Brachtel, Todd R. Golub, Lewis C. Cantley, John M. Asara, Shawn M. Davidson, Dai Fukumura, Véronique A. Dartois, Clary B. Clish, Rakesh K. Jain, Matthew G. Vander Heiden
Journal: Nature Cancer (2021)
865MO RMAC study: A randomized study evaluating the efficacy of metronomic adjuvant chemotherapy in patients with recurrent head and neck cancers post salvage surgery, not eligible for re-irradiation
Authors: N.S. Menon, V.M. Patil, V. Noronha, A. Joshi, V. Mathrudev, A. Bhattacharjee, A. Chandrasekharan, S. Srinivas, D. Vallathol, P. Chaturvedi, D. Chaukar, P. Pai, S. Nair, S.K. Thiagrajan, S. Ghosh Laskar, K. Nawale, S.B. Dhumal, R. Tambe, S. Banavali, K. Prabhash
Journal: Annals of Oncology (2021)
Immunocompromised patients in the USA and UK should receive third dose of COVID-19 vaccine
Authors: Bryant Furlow
Journal: The Lancet Rheumatology (2021)

A third dose of COVID-19 vaccine should be offered to severely immunocompromised people to improve immunogenicity, the UK's Joint Committee on Vaccination and Immunisation (JCVI) advised on Sept 1, 2021. The decision followed similar announcements by the US Food and Drug Administration (FDA) and US Centers for Disease Control and Prevention (CDC) in August.
438P First line treatment patterns in BRAFV600E-mutant metastatic colorectal cancer patients (mCRC): The CAPSTAN European retrospective study
Authors: B. Asselain, E. Martinelli, C. Cremolini, T. Mazard, J. Vidal, I. Virchow, D. Tougeron, C. Castagné, A. Zkik, S. Khan, D. Arnold
Journal: Annals of Oncology (2021)
1386P Phase II study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (pembro) in advanced gastric or gastroesophageal junction (GEJ) cancer
Authors: I. Chau, K. Culm-Merdek, J.C. Bendell, D.V. Catenacci, J. Lee, M.F. Chaney, S. MacIntyre, S. Gopal, V. Chamberlain Santos, H. Youssoufian, C. Mockbee, L. Benjamin, H. Park
Journal: Annals of Oncology (2021)
Traumatic Brain Injury Recovery Trajectories in Patients With Disorders of Consciousness—Reply
Authors: Robert G. Kowalski, John Whyte, Joseph T. Giacino
Journal: JAMA Neurology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
1103P 177Lu-DOTATATE efficacy and safety in functioning neuroendocrine tumors: A joint analysis of phase II prospective clinical trials
Authors: A. Bongiovanni, S. Nicolini, F. Foca, M. Sansovini, I. Grassi, C. Liverani, N. Riva, V. Fausti, L. Mercatali, A. De Vita, L. Fabbri, M. Signoretti, C.A. Pacilio, G. Paganelli, S. Severi, T. Ibrahim, A. Tartaglia
Journal: Annals of Oncology (2021)
A randomized clinical trial on the short‐term effects of 12‐week sacubitril/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the <scp>ACTIVITY‐HF</scp> study
Authors: Martin Halle, Christoph Schöbel, Ephraim B. Winzer, Peter Bernhardt, Stephan Mueller, Christian Sieder, Laura S.M. Lecker
Journal: European Journal of Heart Failure (2021)
336TiP Ipatasertib plus non-taxane chemotherapy for metastatic triple-negative breast cancer (TNBC): Pathfinder trial
Authors: A. Llombart Cussac, J. Soberino, M. Gion, B. Bermejo, M. Martinez- Garcia, S. Braga, F. Cardoso, C. Vieira, E. Lopez-Miranda, M. Sampayo, A. Malfettone, J. Cortés, J.M. Pérez-Garcia
Journal: Annals of Oncology (2021)
Reply to: “Association of chronic liver disease with the prognosis of COVID-19 patients”
Authors: Vincent Mallet, Michaël Schwarzinger, Vincent Mallet, Michaël Schwarzinger, Nathanaël Beeker, Samir Bouam, Hélène Fontaine, Marion Corouge, Anaïs Vallet Pichard, Clémence Hollande, Philippe Sogni, Stanislas Pol
Journal: Journal of Hepatology (2021)
1008P cytoTIL15: A novel TIL therapy for melanoma with superior potency and enhanced persistence without IL2 to improve safety &amp; efficacy and expand patient eligibility
Authors: M. Khattar, R. Burga, K. Pedro, C. Foley, S. Lajoie, A.V. Ocando, J. Tremblay, D. Thornton, S. Tam, F. Nabulsi, C. Vallaster, S. Saha, G. Wilmes, G. Helmlinger, J. Tchaicha, D. Sethi, M. Ols, G. Vanasse, S. Subramanian, J. ter Meulen
Journal: Annals of Oncology (2021)
In postmenopausal women, multimodal or US screening for ovarian cancer did not reduce ovarian cancer mortality
Authors: Pelin Batur
Journal: Annals of Internal Medicine (2021)

Source Citation Menon U, Gentry-Maharaj A, Burnell M, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397:2182-93. 33991479
1573P First wave mortality data versus full pandemic period from the COVID-CANCER HUIL study
Authors: G. Serrano-Montero, J. Rogado, B. Obispo, C. Pangua, A. Lopez-Alfonso, A. Martín-Marino, M. Pérez-Pérez, J.L. García-López, M.A. Lara
Journal: Annals of Oncology (2021)
Tracking COVID-19 Supply Shortages
Authors: Rita Rubin
Journal: JAMA (2021)

COVID-19 Vaccine Nasal SprayAdministering the Oxford/AstraZeneca COVID-19 vaccine through the nose reduced viral shedding in animal models, a recent study led by a National Institute of Allergy and Infectious Diseases (NIAID) scientist found.University of Oxford researchers are now conducting an open-label clinical trial of the intranasal vaccine in healthy human volunteers.All COVID-19 vaccines now in use are injected into muscle, producing antibodies that circulate in the blood but aren't necessarily present in the nose and nasal passages, suggesting that vaccinated individuals could still become infected and transmit the virus.Previous studies in rhesus monkeys showed that the Oxford/AstraZeneca vaccine, which isn't authorized for use in the US, protected against pneumonia but did not reduce shedding from their upper respiratory tract.The authors of the new study first compared the injected and the intranasal vaccines in hamsters.Both routes of administration produced high antibody levels, but the nasal spray outperformed the injection.Vaccinated and unvaccinated hamsters were then exposed to SARS-CoV-2, and both the injected and intranasal vaccines protected hamsters from serious disease.The researchers then gave 2 doses of the intranasal vaccine to 4 rhesus monkeys, who developed antibody levels similar to those seen in people who'd recovered from COVID-19.The 4 vaccinated monkeys, along with 4 unvaccinated rhesus monkeys, were then exposed to SARS-CoV-2.The vaccinated monkeys had less virus in their noses and lung tissue, and none of them developed symptoms of pneumonia, while 3 of the unvaccinated monkeys did.Although the observed differences between the animals that received the intranasal vaccine and the ones that didn't were very encouraging, they weren't significant, the authors noted.Too few animals were vaccinated to establish clear correlations, they wrote.Still, senior author Vincent Munster, PhD, of the NIAID's virology laboratory, said in a statement, "[T]hese results justify addi-
229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study
Authors: M. Martin Jimenez, C. Zielinski, M. Ruiz-Borrego, E. Carrasco, E.M. Ciruelos, M. Muñoz, B. Bermejo, M. Margeli, T. Csoszi, A. Anton, N. Turner, M.I. Casas, S. Morales, E. Alba, L. Calvo, J. De La Haba, M. Ramos, M. Corsaro, Z. Kahan, M. Gil-Gil
Journal: Annals of Oncology (2021)
1712P Safety and efficacy of influenza and pneumococcal vaccines in cancer patients on active therapy: A prospective study
Authors: N.M. La Verde, D. Dalu, A.L. Ridolfo, M.S. Cona, D. De Francesco, A. Riva, S. Antinori, S. Rota, C. Tricella, S. Oldani, C. Fasola, S. Ferrario, A. Gambaro, V. Filipazzi, D. Chizzoniti, M. Cattaneo, F. Di Carlo, B. Lombardi Stocchetti, N. Tosca, M. Galli
Journal: Annals of Oncology (2021)
702P Bladder preservation in elderly with muscle-invasive bladder cancer (MIBC): An observational study with concurrent chemotherapy and twice daily hypofractionated radiation therapy (HFTD) schedule
Authors: A. Alati, E. Fabiano, J.E. Bibault, P. Giraud, A. Mejean, S. Kreps, M. Housset, C. Durdux
Journal: Annals of Oncology (2021)
296P Recapitulation of organ-specific breast cancer metastasis using an engineered multi-tissue platform
Authors: A. Chramiec, E. Öztürk, M. Wang, K. Ronaldson-Bouchard, D.N. Tavakol, K. Yeager, M. Summers, D. Teles, G. Vunjak-Novakovic
Journal: Annals of Oncology (2021)
632P Differential transcriptomic profiling of BCL2-related genes in primary tumor (PT) and metastatic sites (MS) of prostate cancer (PCa)
Authors: B.A. Carneiro, J. Yin, L. Soliman, A. De Souza, D. Golijanin, A. Mega, P.M. Coelho Barata, S. Gulati, S. Wei, D. Geynisman, D. Magee, W.M. Korn, I. Abuali, E. Heath, C.J. Ryan, P. Bertone, W.S. El-Deiry
Journal: Annals of Oncology (2021)
261P Survival outcomes of triple-negative breast cancer (TNBC) patients in the pre-immunotherapy age: An analysis of Gruppo Italiano Mammella (GIM) 14 BIOMETA study with a focus on biological subtypes
Authors: L. Cerbone, E. Blondeaux, L. Boni, T. Ruelle, S. Russo, M. Bonotto, G. Targato, M. De Laurentiis, M. Piezzo, G. Arpino, P. Pugliese, A. Fabi, A. D'Alonzo, I. Giannubilo, B. Conte, C. Mulinelli, M. Lambertini, C. Bighin, L. Del Mastro
Journal: Annals of Oncology (2021)